Literature DB >> 12214826

Attentional processes in abstinent methylenedioxymethamphetamine (ecstasy) users.

Konstantine K Zakzanis1, Donald A Young, Nasim F Radkhoshnoud.   

Abstract

In recent years, methylenedioxymethamphetamine (MDMA or ecstasy) has gained great popularity among young adults. Although human research in abstinent users has focused primarily on memory function, little attention has been given to other neuropsychological functions that may have some bearing on memory performance, such as attention. Hence, the purpose of this study was to examine the effects of MDMA on attentional processes. Accordingly, 24 MDMA users and 30 matched normal controls were tested on the Wechsler Abbreviated Scale of Intelligence (WASI) and the Test of Everyday Attention (TEA). We found MDMA users to show generally no significant difference on attention tasks compared with controls with the exception of a single TEA subtest. More interestingly, we found some preliminary evidence to indicate that dosage, in terms of the number of tablets used, may be related to impairment on specific component attentional tasks. This finding brings to light the important relationship between poor attentional processes and drug-taking behaviors and their reciprocal relationship.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12214826     DOI: 10.1207/S15324826AN0902_3

Source DB:  PubMed          Journal:  Appl Neuropsychol        ISSN: 0908-4282


  2 in total

1.  Memory-related hippocampal dysfunction in poly-drug ecstasy (3,4-methylenedioxymethamphetamine) users.

Authors:  Jörg Daumann; Thomas Fischermann; Karsten Heekeren; Katharina Henke; Armin Thron; Euphrosyne Gouzoulis-Mayfrank
Journal:  Psychopharmacology (Berl)       Date:  2005-09-14       Impact factor: 4.530

2.  MDMA (ecstasy) use is associated with reduced BOLD signal change during semantic recognition in abstinent human polydrug users: a preliminary fMRI study.

Authors:  V Raj; H C Liang; N D Woodward; A L Bauernfeind; J Lee; M S Dietrich; S Park; R L Cowan
Journal:  J Psychopharmacol       Date:  2009-03-20       Impact factor: 4.153

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.